Rapt stock skyrocketed Monday after the biotech company said its experimental hives treatment topped Roche'sRHHBY Xolair in a head-to-head 16-week study. Rapt TherapeuticsRAPT tested two doses of its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback